Palo Alto-based Risa Labs announced the closing of an $11.1 million Series A funding round to scale up its AI operating system for oncology across the United States.
RISA Labs is developing the BOSS Console, an AI-driven “operating system” designed to manage end-to-end oncology workflows.
With fresh funds, Risa Labs plans to expand its AI orchestration platform across the entire oncology ecosystem, enabling better coordination between providers, life sciences organizations, and other stakeholders throughout the drug lifecycle.
The financing was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon (co-founder of General Catalyst) via his Ventureforgood investment entity.